The company delays EU vaccine deliveries as US pauses use over blood clots.
Johnson & Johnson is to pause deliveries of its single-shot COVID-19 vaccine in Europe pending an investigation of rare blood clot cases that have halted rollout in the US, it announced. “We have been reviewing these cases with European health authorities,” the company said in a statement. “We have made the decision to proactively delay the rollout of our vaccine in Europe.”
Six cases were detected in more than 6.8 million doses of the vaccine, the US Food and Drug Administration (FDA) said. The FDA said it was recommending the temporary pause “out of an abundance of caution”. It confirmed that one patient died from blood clotting complications, and another is in a critical condition. The cases all occurred in women aged between 18 and 48, with symptoms occurring 6 to 13 days after vaccination, according to the US Food and Drug Administration (FDA).